Fluoropharma Medical is engaged in the discovery, development, and commercialization of molecular imaging pharmaceuticals with primary applications in the area of cardiology. The company’s BFPET is in phase I trial used for the detection of ischemic and infarcted tissue within the myocardium in patients with suspected or proven chronic CAD. CardioPET is in phase II development stage for the assessment of myocardial metabolism. For further information, visit the company’s Web site at: www.fluoropharma.com

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its ninth annual equity conference at The Hard Rock Hotel in Ft. Lauderdale, FL. Attended by institutional investors from across North America, the event features 135 public company executive teams with an emphasis on healthcare, technology, defense, and new-media / entertainment sectors.

Let us hear your thoughts below: